中国10月CPI由降转涨，高于预期，"反内卷"行业价格积极改善。港股三大指数高开，恒指涨0.3%，国 指涨0.26%，恒生科技指数涨0.36%。大型科技股走势分化，阿里巴巴涨近2%，腾讯涨约1%，京东、百 度小幅走低；生物医药板块涨幅居前，其中，君实生物高开超3%，锂电池股、汽车股活跃，天齐锂 业、赣锋锂业齐涨。另外，黄金股、苹果概念股、内险股多数下跌。新股乐舒适高开33.51%。(格隆汇) ...

Major Events - Bluestar Jiahe Services (02606.HK) plans to repurchase up to 10% of its issued H-shares [1] - China People's Insurance Group (01339.HK) reported original premium income of 97.985 billion yuan in January, a year-on-year increase of 6.67% [1] - Hengteng Network (00136.HK) signed a strategic cooperation agreement with Evergrande Tourism Group [1] Financial Data - New Star Printing (01975.HK) achieved a net profit of 27.5 million HKD in the interim period, with an interim dividend of 1.5 HKD cents [1] Earnings Forecast - Qihua Environmental Protection (00976.HK) expects an increase in annual net loss [1] - Zhuyou Intelligent Manufacturing Technology (00726.HK) anticipates a net profit increase of approximately 40.8% for the year [1] - Birmingham Sports (02309.HK) raised its earnings forecast, expecting a mid-term profit of 70 million HKD [1] - Huazhang Technology (01673.HK) expects a mid-term profit of 15 to 20 million yuan, turning from loss to profit year-on-year [1] - Raffles Interior (01376.HK) anticipates a net loss of 4.5 million Singapore dollars for the 2020 fiscal year [1] - Fengcheng Holdings (08216.HK) expects a net profit increase of over 50% for the year [1] - New Fengtai Group (01771.HK) forecasts a net profit growth of approximately 20% for the year [1] - Yefeng Group (01695.HK) expects an annual loss not exceeding 4 million Malaysian ringgit [1] Operational Data - China People's Insurance Group (01339.HK) reported original premium income of 97.985 billion yuan in January, a year-on-year increase of 6.67% [1] - New China Life Insurance (01336.HK) reported original premium income of 34.63 billion yuan in January, a year-on-year increase of 12.78% [1] - China Property & Casualty Insurance (02328.HK) reported original insurance premium income of 53.112 billion yuan in January, a year-on-year increase of 1.2% [1] - China Metallurgical Group (01618.HK) signed new contracts worth 103.59 billion yuan in January, a year-on-year increase of 129.7% [1] - China Eastern Airlines (00670.HK) reported a 60.59% year-on-year decline in passenger turnover in January [1] - Sinopec Oilfield Services (01033.HK) recently signed overseas contracts worth 2.323 billion yuan [1] - China Southern Airlines (01055.HK) reported a 59.16% year-on-year decline in passenger turnover in January [1] - Huili Group (00806.HK) reported total managed assets of approximately 14.8 billion USD at the end of January [1]

88888888 ...

Core Insights - The article presents a ranking of 78 unprofitable biotechnology companies listed in Hong Kong, highlighting their market capitalizations and stock prices as of October 31, 2025 [1][2][3]. Market Capitalization Summary - The top three companies by market capitalization are: 1. 名要放田 (Ming Yao Fang Tian) with a market cap of HKD 286.26 billion 2. 信达生物 (Innovent Biologics) with a market cap of HKD 149.08 billion 3. 科伦博泰生物-B (Kintor Pharmaceutical) with a market cap of HKD 104.47 billion [1][2]. Price Performance Summary - The highest price increase for the year is observed in: 1. 北海康成-B (Beihai Kangcheng) with a price increase of 1381.20% 2. 药康安康 - B (Yao Kang An Kang) with a price increase of 1297.72% 3. 三叶草生物-B (San Ye Cao) with a price increase of 812.86% [3][4]. Additional Performance Insights - Other notable performers include: - 德棋医药-B (Deqi Pharmaceutical) with a 696.92% increase - 和铂失药-B (He Bo Shi Yao) with a 624.19% increase - 荣昌生物 (Rongchang Biologics) with a 525.00% increase [3][4]. Overall Trends - The article indicates a significant volatility in the biotechnology sector, with many companies experiencing substantial price fluctuations, reflecting investor sentiment and market dynamics [3][4].

中国经济网北京11月7日讯 君实生物(688180.SH)今日收报37.79元，跌幅1.92%。该股目前处于破发 状态。 经计算，君实生物两次募集资金合计86.12亿元。 2016年至2024年，君实生物归属于上市公司股东的净利润分别为-1.35亿元、-3.17亿元、-7.23亿 元、-7.47亿元、-16.69亿元、-7.21亿元、-23.88亿元、-22.83亿元、-12.81亿元；归属于上市公司股东的 扣除非经常性损益的净利润分别为-1.60亿元、-3.00亿元、-7.06亿元、-7.76亿元、-17.09亿元、-8.84亿 元、-24.50亿元、-22.98亿元、-12.90亿元。 2025年前三季度，公司实现营业收入18.06亿元，同比增长42.06%；归属于上市公司股东的净利润 为-5.96亿元，上年同期为-9.27亿元；归属于上市公司股东的扣非净利润为-6.7亿元，上年同期为-9.4亿 元；经营活动产生的现金流量净额为-3.43亿元，上年同期为-11.13亿元。 （责任编辑：关婧） 君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿 元，较原计划多1 ...

来源：新浪基金∞工作室 11月7日，君实生物跌1.92%，截至发稿，报37.79元/股，成交2.92亿元，换手率1.00%，总市值387.99亿 元。君实生物股价已经连续5天下跌，区间累计跌幅6.39%。 截至发稿，李会忠累计任职时间11年116天，现任基金资产总规模2.33亿元，任职期间最佳基金回报 70.73%， 任职期间最差基金回报-39.92%。 王毕功累计任职时间361天，现任基金资产总规模9416.11万元，任职期间最佳基金回报1.11%， 任职期 间最差基金回报0.73%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 从基金十大重仓股角度 数据显示，格林基金旗下1只基金重仓君实生物。格林鑫悦一年持有期混合A（011775）三季度持有股 数3.3万股，占基金净值比例为1.45%，位居第九大重仓股。根据测算，今日浮亏损失约2.44万元。连续 5天下跌期间浮亏损失8.51万元。 格林鑫悦一年持有期混合A（011775）成立日期2021年6月9日，最新规模573 ...

Investment Rating - The report indicates a positive outlook for the non-ferrous metals industry, with a focus on ESG performance management among central enterprises [3][4]. Core Insights - The report evaluates 18 central enterprises in the non-ferrous metals sector based on an established ESG rating system, highlighting that 11 companies scored over 100 points, reflecting a systematic approach to ESG management [4][12]. - Environmental management is prioritized, with comprehensive disclosure on pollution control, waste management, and energy utilization, although there is room for improvement in areas like green mining and circular economy indicators [4][24]. - The report emphasizes the importance of climate-related governance, with many companies actively addressing climate change and setting reduction targets, though mechanisms for information acquisition need enhancement [4][42]. - Social responsibility is a key focus, with all companies covering social indicators, but there is a noted deficiency in disclosures related to technology ethics [4][61]. - Governance structures are generally robust, but there is a need for improvement in due diligence practices, particularly concerning compliance checks of supply chain partners [4][75]. Summary by Sections 1. Overall Scores and ESG Governance - The overall ESG scores for the 18 central enterprises are high, with 61.1% scoring above 100 points, indicating a well-established ESG management framework [12]. 2. Importance Assessment: Need for Third-Party Verification - All companies disclosed financial and impact importance assessments, but only 11% provided third-party verification, indicating a gap in independent validation [16][17]. 3. Environmental: Mature Disclosure, Comprehensive Management - Environmental indicators show high scores, with 67% of companies achieving full marks, reflecting strong environmental protection awareness [24][27]. 4. Climate: Accelerating Disclosure Framework - 67% of companies received full scores for climate-related disclosures, demonstrating a high level of commitment to addressing climate change [42][49]. 5. Social: Commitment to Social and Management Responsibilities - Social responsibility indicators are fully covered by all companies, but technology ethics disclosures are lacking [61][64]. 6. Governance: Well-Structured, Need for Enhanced Due Diligence - Governance structures are generally well-defined, with high coverage of governance mechanisms, but due diligence practices require further development [75][76].

来源：新浪基金∞工作室 11月7日，君实生物跌1.92%，截至发稿，报37.79元/股，成交2.92亿元，换手率1.00%，总市值387.99亿 元。君实生物股价已经连续5天下跌，区间累计跌幅6.39%。 资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售90.67%，技术许可及特许权使用收入8.74%，技术服务及其他 0.59%。 成曦累计任职时间9年187天，现任基金资产总规模2501.21亿元，任职期间最佳基金回报131.04%， 任 职期间最差基金回报-67.89%。 从君实生物十大流通股东角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 易方达上证科创板50ETF（58 ...

来源：新浪基金∞工作室 11月7日，君实生物跌1.92%，截至发稿，报37.79元/股，成交2.92亿元，换手率1.00%，总市值387.99亿 元。君实生物股价已经连续5天下跌，区间累计跌幅6.39%。 资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售90.67%，技术许可及特许权使用收入8.74%，技术服务及其他 0.59%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 前海联合国民健康混合A（003581）成立日期2016年12月29日，最新规模1564.76万。今年以来收益 6.95%，同类排名6475/8148；近一年收益0.76%，同类排名7710/8053；成立以 ...

Core Viewpoint - The company, Junshi Biosciences, aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation in drug development [2][3]. Company Overview - Junshi Biosciences was founded on December 27, 2012, and went public on July 15, 2020. Its main business involves the research and commercialization of monoclonal antibody drugs and other therapeutic proteins, with 90.67% of revenue coming from drug sales [7]. - As of September 30, 2025, the company reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [8]. Product Development - The company has developed a strong portfolio of innovative drugs, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2]. - Junshi Biosciences is also advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Collaborations and Research - The company is collaborating with institutions such as Peking University and the Chinese Academy of Sciences to develop vaccines, including a monkeypox vaccine, which is currently in the preclinical development stage [3][8]. Market Performance - On November 7, the company's stock fell by 1.92%, with a trading volume of 292 million yuan and a market capitalization of 38.799 billion yuan [1]. - The stock has seen a net outflow of 458.376 million yuan from major investors, indicating a trend of reduced holdings over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 41.33 yuan, with the current price approaching a resistance level of 38.99 yuan, suggesting potential volatility in the near term [6].